1 |
Khosla S, Burr D, Cauley J. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
DOI
PUBMED
ScienceOn
|
2 |
Wilkinson G, Kuo YF, Freeman KJ. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016-24
DOI
PUBMED
ScienceOn
|
3 |
Drexler HC, Risaw W, Konerding MA.: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;20:4319-23
PUBMED
|
4 |
Schulze D, Blessmann M, Pohlenz P. Diagnostic criteria for the detection of mandibular osteomyelitis using cone-beam computed tomography. Dentomaxillofac Radiol 2006;35:232-5
DOI
PUBMED
ScienceOn
|
5 |
Wutzl A, Eisenmenger G, Hoffmann M. Osteonecrosis of the jaws and bisphosphonate treatmentin cancer patients. Wien Klin Wochenschr 2006;118:473-8
DOI
PUBMED
ScienceOn
|
6 |
Rizzoli R, Pierre D, Burlet NS. Review: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42: 841-7
DOI
PUBMED
ScienceOn
|
7 |
Chhoeu AH, Siegel D. Landesberg R, Althoff M. A case series of hyperbaric oxygen treatment for non-radiation induced osteonecrosis of the jaw. J Oral MaxillofacSurg. 2006;64(Sup):80-1
DOI
ScienceOn
|
8 |
Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34(Suppl 4):S17-S23
DOI
PUBMED
ScienceOn
|
9 |
Migliorati CA, Casiglia J, Epstein J. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J AM Dent Assoc 2005;136:1658-68
PUBMED
|
10 |
Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-23
DOI
PUBMED
ScienceOn
|
11 |
Yarom N, Yahalom R, Shoshani Y. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-70
DOI
PUBMED
ScienceOn
|
12 |
Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphophonates: current issues. J Support Oncol 2007;5:475-82
PUBMED
|
13 |
Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone 2006;38:613-6
DOI
PUBMED
ScienceOn
|
14 |
Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonate. Med 2005;353:99-102
DOI
PUBMED
|
15 |
Ruggiero SL, Mehrotra B, Rosenberg TJ. Osteonecrosis of the jaws associated with the use of bisphosphonates : a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34
DOI
PUBMED
ScienceOn
|
16 |
Phal PM, Myall RW, Assael LA. Imaging findings of bisphoshonate-associated osteonecrosis of the jaws. Am J Neuroradiol 2007;28:1139-45
DOI
PUBMED
ScienceOn
|
17 |
Reid IR. Bolland MJ. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20
DOI
PUBMED
ScienceOn
|
18 |
Kwon YD, Yoon BW, Walter C. Bisphosphonate, is it an emerging risk factor in oral surgery? J Kor Maxillofac Plastic Recon Surg 2007;29:456-62
과학기술학회마을
|
19 |
Marx RE. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. 1st ed. Chicago: Quintessence Publishing, 2007
|
20 |
Rogers MJ, Gordon S, Benford HL. Cellular and molecular mechanism of action of bisphosphonates. Cancer 2000: 88(Suppl): 2961-78
PUBMED
|
21 |
Mavrokokki A, Cheng A, Stein B. Nature and frequency of bisphosphonate -associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23
DOI
PUBMED
ScienceOn
|
22 |
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76
DOI
PUBMED
ScienceOn
|
23 |
Guerrero ME, Jacobs R, Loubele M. State-of-the-art on cone beam CT imaging for preoperative planning of implant placement. Clin Oral Investig 2006;10:1-7
DOI
PUBMED
ScienceOn
|
24 |
Marx RE, Sawatari Y, Fortin M. BroumanV.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567-75
DOI
PUBMED
ScienceOn
|
25 |
Marx RE. Pamidronate (AREDIA) and zoledronate(ZOMETA) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115 -8
DOI
PUBMED
ScienceOn
|
26 |
Lam DK, Sandor GK, Holmes HI. A review of bisphos phonate - associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73: 417-22
PUBMED
|
27 |
Berenson JR, Hillner BE, Kyle RA, American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Clin Oncol 2002;20:3719-36
DOI
PUBMED
ScienceOn
|
28 |
Owens G, Jackson R, Lewiecki EM. An integrated approach:bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007;13 Suppl 11): S290-S308
PUBMED
|
29 |
Woo SB, Hellstein JW, Kalmar JR. Systematic review:bisphosphonate and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61
DOI
PUBMED
ScienceOn
|